Intrinsiqq
Johnson & Johnson logo

Johnson & Johnson Financials

JNJ

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 20 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
JAN 2023
JAN 2022
Revenues
Revenue$99,335$94,193$88,821$85,159$79,990$78,740
Cost of Revenue$32,222$30,256$27,471$26,553$24,596$23,402
Gross Profit$67,113$63,937$61,350$58,606$55,394$55,338
General & Administrative$25,504$23,676$22,869$21,512$20,246$20,118
Research & Development$16,084$14,665$17,232$15,085$14,135$14,277
Provision for Doubtful Accounts$10-$1$11$0-$17-$48
Total Operating Expenses$73,810$68,597$67,572$63,150$58,977$57,797
Operating Income$25,525$25,596$21,249$22,009$21,013$20,943
Non-Operating
Net Interest Expense-$113$85$577$489$214-$130
Other Non-Operating Income (Expense)-$7,675$6,900-$5,139-$7,436-$1,868-$1,635
EBT (Earnings Before Tax)$17,737$32,581$16,687$15,062$19,359$19,178
Income Tax Expense$1,642$5,777$2,621$1,736$2,989$1,377
Earnings from Continuing Ops–$26,804$14,066$13,326$16,370$17,801
Net Income
Net Income$16,095$26,804$14,066$35,153$17,941$20,878
Per Share Data
Revenue Per Share$40.57$38.77$36.56$33.26$30.03$29.45
EPS (Basic)$6.68$11.13$5.84$13.88$6.83$7.93
EPS (Diluted)$6.58$11.03$5.79$13.72$6.73$7.81
Weighted Avg Shares (Basic)2.41B2.41B2.41B2.53B2.63B2.63B
Weighted Avg Shares (Diluted)2.45B2.43B2.43B2.56B2.66B2.67B
Shares Outstanding2.45B2.43B2.43B2.56B2.66B2.67B
Dividends Per Share$5.28$5.14$4.91$4.70$4.45$4.19

Johnson & Johnson (JNJ) financials: revenue, profit and margins

Johnson & Johnson (JNJ) generated about $99.3 billion in revenue and $16.1 billion in net income (a 16.2% net margin) over the trailing twelve months, growing at roughly 2.7% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Johnson & Johnson's (JNJ) revenue?+

Johnson & Johnson generated about $99.3 billion in revenue over the trailing twelve months. Revenue has grown at roughly 2.7% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Johnson & Johnson profitable?+

Yes, Johnson & Johnson reported about $16.1 billion in net income over the trailing twelve months, a net profit margin of roughly 16.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Johnson & Johnson's profit margins?+

Johnson & Johnson runs a gross margin of about 67.6%, an operating margin of about 25.7%, a net margin of about 16.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Johnson & Johnson growing?+

Johnson & Johnson's revenue has compounded at roughly 2.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside JNJ's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 15 Oct 2026, covering the period ending 27 Sept 2026, as reported to the SEC. Data last refreshed 22 Oct 2026. How this is calculated.

Fiscal year ends Jan.

Peers

Pharmaceutical Preparations · Pick stocks to compare with JNJ

CompareIntrinsic value
LLYEli Lilly and Company
$1,418.07+0.62%73
MRKMerck & Co., Inc.
$150.36+3.93%41
ABBVAbbVie Inc.
$294.83+3.09%49
PFEPfizer Inc.
$30.79+2.63%30
BMYBristol-Myers Squibb Company
$64.20+4.04%61
ABTAbbott Laboratories
$115.55+5.62%25
UPCUniverse Pharmaceuticals Inc.
$1.47-1.34%39
TEVATeva Pharmaceutical Industries Ltd
$42.13+0.52%46

Held by ETFs

JNJ is in 485 US ETFs. The largest of them, with JNJ's weight in each:

Spot a number that looks wrong? Check it in JNJ's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing JNJ

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.